



Zent2U announces successful pivotal bioequivalence study results on Omeprazole Immediate Release Capsules

Zent2U is delighted to announce to all our dear business partners and future business partners successful completion of Omeprazole 20 mg IR Capsules pivotal bioequivalence study.

Our new value added formulation of Omeprazole, containing antacid, protects the active substance against stomach acid and accelerates its absorption.

The study proved the comparative bioavailability of novel immediate release formulation versus the classical delayed release form of Omeprazole.

Having completed the clinical studies successfully, we are now compiling EU dossier, available for customer's review in early Q1 2023.

We believe that having the dossier in place in early 2023 grants Zent2U and its partners the great opportunity to register this product in all major EU markets at the earliest possible time, and complement their portfolios with a high potential value added product, indicated for treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.

Partner up now and connect with our team today!



Thomas Koene

Head of Strategic Growth Partnerships

thomas.koene@zentiva.com



Tomas Pilarcik

Head of B2B Europe

tomas.pilarcik@zentiva.com



Rahul Padhye

Head of B2B International

rahul.padhye@zentiva.com



Nina Fuentes

Key Account Manager B2B Europe

nina.fuentes@zentiva.com



Clara Vitaller

Senior BD Manager B2B

clara.vitaller@zentiva.com